ICCM — IceCure Medical Ltd.

Is ICCM overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of August 19, 2026

IceCure Medical Ltd. (ICCM) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $2.60. The rating moved from Neutral to Oversold on August 14, 2026.

See all oversold Healthcare stocks →

AI analysis

IceCure Medical Ltd. (ICCM) is a small-cap medical device company focused on cryoablation technology with niche clinical applications. The company’s technical differentiation and potential clinical/regulatory catalysts create upside if trials and reimbursement progress, but commercialization is presently limited and the business is sensitive to funding and adoption risks. Market sentiment for growth healthcare names is cautiously constructive, which could amplify moves on positive news; however, clinical/regulatory setbacks, dilution risk, and competitive dynamics are material near-term threats. Monitor upcoming clinical milestones, cash runway and partnership/reimbursement developments to reassess trajectory.

Key factors

  • Proprietary cryoablation technology with clear clinical use cases in benign and potentially malignant tumors provides differentiated product positioning.
  • Commercialization remains limited and concentrated; meaningful revenue expansion depends on successful adoption, reimbursement, and expanded clinical indications.
  • Regulatory and clinical milestones (trial readouts, approvals or IDE progress) are primary near-term catalysts that could materially change valuation.
  • Small‑cap / microcap structure with low liquidity increases share-price sensitivity to news, funding events, and broader market risk sentiment.
  • Recent constructive market tone for growth-oriented healthcare names could support investor interest in small medtech names on positive clinical updates.

Risks

  • Clinical or regulatory setbacks (negative trial data, slowed approvals or additional study requirements).
  • Weak financial position or limited cash runway leading to dilution through equity raises or unfavorable financing terms.
  • Slow commercial adoption due to reimbursement uncertainty, entrenched alternatives, or limited sales/marketing infrastructure.
  • High stock price volatility and low trading volume increasing execution and exit risk for investors.
  • Competition from other ablation technologies and evolving standards of care that could limit addressable market or margin potential.

See today's live rating, score and targets

Members see the live hourly rating for ICCM — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.